Xenon Pharmaceuticals Inc
(FRA:XP0)
€
52.5
-0.50 (-0.94%)
Market Cap: 5.38 Bil
Enterprise Value: 4.18 Bil
PE Ratio: 0
PB Ratio: 4.37
GF Score: 25/100 Xenon Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 19, 2026 / 01:30PM GMT
Brian Abrahams
RBC Capital Markets Inc - Managing Director
Hi, again, everyone. I'm Brian Abrams, Senior Biotech Analyst here at RBC Capital Markets. We're really pleased to have our next featured company, Xenon Pharmaceuticals, represented by their President and CEO, Ian Mortimer, and their CFO, Tucker Kelly. Ian and Tucker, thank you guys so much for being here.
Ian Mortimer
Xenon Pharmaceuticals Inc - President, Chief Executive Officer, Interim Chief Financial Officer, Director
Thanks, Brian. Thank you.
Questions & Answers
Brian Abrahams
RBC Capital Markets Inc - Managing Director
All right. So, it's been a really exciting year so far for you guys with some of the data we've seen from Azetukalner and the X-TOLE2 at the Phase 3 focal onset epilepsy study. And the data that you released in March demonstrated a very impressive efficacy at 43% placebo-adjusted seizure reduction at the highest dose. You got to 7% of patients to complete remission.
What's been the reactions that you guys have
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot